drugset / Trial / NCT03309202

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

NCT03309202

Phase 1 Completed 24 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Hepatic impairment PK study

Timeline

Start
2017-12-19
Primary completion
2018-06-26
Completion
2018-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Clesacostat Small molecule 25 mg Oral